Clinical Trials
10 trialsNCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT04233346 2025-04-04
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Otsuka Beijing Research Institute
Phase 2 Active not recruiting
NCT05286528 2023-10-27
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Pfizer
Completed
NCT03709017 2022-12-07
Iclusig PMS in CML or Ph+ALL Patients
Korea Otsuka Pharmaceutical Co., Ltd.
Unknown
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT01207440 2021-02-02
PACE
Takeda
Phase 2 Completed
NCT00660920 2018-05-16
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
Takeda
Phase 1 Completed
NCT01592136 2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated